Looks like you’re on the UK site. Choose another location to see content specific to your location
Boston Scientific to present new clinical data at TCT 2017
Boston Scientific has announced plans to present new clinical data on a number of cardiac devices at the Transcatheter Cardiovascular Therapeutics (TCT) conference.
The event, which serves as the annual scientific symposium of the Cardiovascular Research Foundation, will be held in Denver from October 29th to November 2nd, and will see the company share insights into its cardiovascular portfolio.
The firm's Watchman left atrial appendage closure (LAAC) device will be a key area of focus, with a late-breaking clinical trial session highlighting five-year outcomes from PREVAIL, a trial comparing LAAC to medical therapy in patients with non-valvular atrial fibrillation.
Additionally, five-year follow-up data from the Continued Access to PROTECT AF (CAP) registry will be shared, demonstrating long-term event rates associated with Watchman, as well as a sub-analysis from the PLATINUM Diversity study, which addresses predictors of cardiac event risk following percutaneous coronary intervention in minority women.
Professor Ian Meredith, executive vice-president and global chief medical officer at Boston Scientific, said: "We look forward to continuing the important dialogue around the Watchman LAAC Device as an alternative option to long-term warfarin therapy for patients with non-valvular atrial fibrillation who are seeking another treatment to reduce their risk of stroke."
With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard